OPKO’s Bevasiranib Named One Of Most Promising Drugs Recently Entering Phase III Trials

OPKO Health, Inc. (Amex: OPK) reported that the gene silencing agent bevasiranib, OPKO’s lead compound for the treatment of wet age-related macular degeneration (wet AMD), was named one of the top five most promising drugs entering Phase III clinical trials during the third quarter of 2007. The designation was reported in the current issue of The Ones to Watch report issued by Thomson Scientific Inc. [click link for full article]

More: continued here

Filed under: Eye Health on December 9th, 2007